The goal of this review article is to summarize the current literature and to define the outstanding areas of research that need to be explored to advance our ability to predict when HAPE will occur. Copyright (C) 2012 S. Karger AG,
Basel”
“Background: Quality-of-care indicators are measurable elements of practice performance that can be used to assess the quality or change in quality of the care provided. To date, the literature on quality-of-care indicators for non-small selleck chemicals cell lung cancer (NSCLC) has not been reviewed.
Methods: A search was performed to identify articles reporting on quality-of-care indicators specific for NSCLC published from January 2003 to May 2009 (using MEDLINE and American Society of Clinical Oncology abstract databases). Web sites of major quality care organizations were also searched. The identified indicators were then classified by their aspect of care provision (structure-of-care, process-of-care, or outcome-of-care indicator).
Results: For structure-of-care quality indicators, the most cited indicators were related to the quality of lung surgery. These included being National Cancer Institute-designated cancer centers or high-volume
hospitals. For process-of-care quality indicators, the most common indicators were the receipt of surgery for early-stage NSCLC and the administration of chemotherapy for advanced-stage NSCLC. For outcome-of-care quality indicators, the most cited indicators were related to postoperative morbidity or mortality after lung surgery.
Conclusions: Several quality-of-care indicators for NSCLC are available. Process-of-care LY294002 inhibitor indicators are the most studied. The use of these indicators to measure practice performance holds the promise of improving outcomes of patients with NSCLC.”
“ObjectiveTo compare success rates between anterior colporrhaphy and abdominal paravaginal defect repair for treatment of anterior vaginal wall prolapse.
MethodsThis was a prospective randomized controlled trial comparing anterior colporrhaphy plus polyglactin 910mesh (vaginal) to WZB117 clinical trial paravaginal defect repair (abdominal) in women with symptomatic anterior vaginal wall prolapse. Pelvic organ prolapse quantification staging (POP-Q),
pelvic floor distress inventory, pelvic floor impact questionnaire, and pelvic organ prolapse/urinary incontinence sexual questionnaires were administered pre and post-operatively. Women were followed up to 2 years. The primary outcome was anterior POP-Q stage, with failure defined as stage II.
ResultsWe enrolled 70 patients, 35 in each group. Demographic and most peri-operative characteristics were similar between the groups. Mean anterior vaginal wall prolapse repair time (39min) was shorter for vaginal versus abdominal repair (60min; P<0.001), with more concurrent hysterectomies in the vaginal (71%) versus abdominal group (42%), P=0.01. At 2 years, objective failure rates for the vaginal and abdominal groups were 32% and 40%, respectively, P=0.56.